Phathom Pharmaceuticals (PHAT)

• Market cap: $1.04B
• 1 day: -0.07%
• 5 days: -1.62%
• 1 month: -0.41%
• 3 months: 22.97%
• 6 months: 45.16%
• Year to date: 98.64%
• 1 year: 82.23%
• 5 years: -67.25%
• 10 years: -40.81%
• Sector: Healthcare
• Industry: Biotechnology

About: Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Employees: 427